Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
CoTec to Form an Early Stage Exploration Joint Venture with U.S. Company Copper Intelligence to Target Processing Historical Copper Tailings Opportunities in the Democratic Republic of Congo
Analyst Note: Positive PEA Delivered - Rua Gold's Auld Creek Enters PFS Workstream Under New Zealand Fast-Track Approvals
Analyst Note: Positive PEA Delivered - Rua Gold's Auld Creek Enters PFS Workstream Under New Zealand Fast-Track Approvals
